Ocugen Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Ocugen's earnings have been declining at an average annual rate of -21.4%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 80.2% per year.
Belangrijke informatie
-21.4%
Groei van de winst
68.0%
Groei van de winst per aandeel
| Biotechs Groei van de industrie | 17.0% |
| Inkomstengroei | 80.2% |
| Rendement op eigen vermogen | -294.7% |
| Nettomarge | -618.2% |
| Volgende winstupdate | 08 Nov 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Ocugen announces peer-reviewed publication on COVID-19 vaccine
Sep 14Ocugen initiated with Buy at Mizuho citing favorable setup ahead of key readout
Aug 23Ocugen Q2 2022 Earnings Preview
Aug 04Ocugen: A First Take
Jul 18Ocugen in renewed focus as FDA wants COVID boosters to fight Omicron variant
Jul 05Opbrengsten en kosten
Hoe Ocugen geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 7 | -45 | 28 | 0 |
| 31 Mar 24 | 7 | -58 | 30 | 0 |
| 31 Dec 23 | 6 | -63 | 32 | 0 |
| 30 Sep 23 | 3 | -82 | 34 | 0 |
| 30 Jun 23 | 3 | -90 | 34 | 0 |
| 31 Mar 23 | 3 | -86 | 34 | 0 |
| 31 Dec 22 | 2 | -87 | 35 | 0 |
| 30 Sep 22 | 0 | -74 | 36 | 0 |
| 30 Jun 22 | 0 | -63 | 32 | 0 |
| 31 Mar 22 | 0 | -69 | 29 | 0 |
| 31 Dec 21 | 0 | -58 | 23 | 0 |
| 30 Sep 21 | 0 | -48 | 18 | 0 |
| 30 Jun 21 | 0 | -47 | 15 | 0 |
| 31 Mar 21 | 0 | -38 | 10 | 0 |
| 31 Dec 20 | 0 | -34 | 8 | 0 |
| 30 Jun 20 | 0 | -30 | 8 | 1 |
| 31 Mar 20 | 0 | -18 | 7 | -3 |
| 31 Dec 19 | 0 | -20 | 6 | 0 |
| 30 Sep 19 | 0 | -39 | 6 | 9 |
| 30 Jun 19 | 0 | -18 | 6 | 4 |
| 31 Mar 19 | 0 | -19 | 6 | 11 |
| 31 Dec 18 | 0 | -18 | 6 | 10 |
Kwaliteitswinsten: OCGN is currently unprofitable.
Groeiende winstmarge: OCGN is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: OCGN is unprofitable, and losses have increased over the past 5 years at a rate of 21.4% per year.
Versnelling van de groei: Unable to compare OCGN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: OCGN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Rendement op eigen vermogen
Hoge ROE: OCGN has a negative Return on Equity (-294.74%), as it is currently unprofitable.